Xconomy | Boston - Business + Technology in the Exponential Economy

Life Science, RNAi, Patents

Alnylam to Receive European Patent

Ryan McBride 4/20/09

Alnylam Pharmaceuticals (NASDAQ:ALNY), a Cambridge, MA-based developer of RNA-interference (RNAi) drugs, says that the European Patent Office will grant the firm a patent related to its “Tuschi I” patent series covering the use of double-stranded RNA molecules for RNA-interference. The patent, which the company expects to be issued in four months, covers claims such as the use of RNAi to reduce expression of a gene with double-stranded RNA molecules of 21 to 23 nucleotides in length.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.